Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 16/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.34 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL732160 | 0.80 | CYP19A1 (0.41) | CYP19A1CYP11B1CYP11B2KCNH2 | |
| SCHEMBL729936 | 0.71 | CYP19A1 (0.45) | CYP19A1CYP11B1CYP11B2KCNH2 | |
| SCHEMBL732357 | 0.71 | CYP19A1 (0.36) | CYP19A1CYP11B1CYP11B2KCNH2 | |
| SCHEMBL21672501 | 0.64 | CYP19A1 (0.31) | CYP19A1 | |
| SCHEMBL18702957 | 0.64 | LMNA (0.43) | — | |
| SCHEMBL2619374 | 0.62 | LMNA (0.49) | — | |
| SCHEMBL2915017 | 0.61 | CYP17A1 (0.42) | CYP19A1CYP3A4BAZ2BKCNJ1 | |
| SCHEMBL1181751 | 0.61 | CYP17A1 (0.62) | CYP19A1CYP3A4BAZ2BKCNJ1 | |
| SCHEMBL29847538 | 0.59 | KMT2A (0.43) | — | |
| SCHEMBL12883115 | 0.59 | SERPINE1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138176-B2 | Imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-8138176-B2 | Imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-8138176-B2 | Imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | HEROLD PETER | 2011-04-21 | — | — | US | disclosed |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | HEROLD PETER | 2011-04-21 | — | — | US | disclosed |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | HEROLD PETER | 2011-04-21 | — | — | US | disclosed |
| US-7879847-B2 | such as 4-(5,6-Dihydro-8H-imidazo[5,1-c][1,4]oxazin-5-yl)benzonitrile, having aldosterone synthase and/or 11- beta -hydroxylase inhibitory activity, used for the treatment of hypertension and Cushing's Syndrome | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| US-7879847-B2 | such as 4-(5,6-Dihydro-8H-imidazo[5,1-c][1,4]oxazin-5-yl)benzonitrile, having aldosterone synthase and/or 11- beta -hydroxylase inhibitory activity, used for the treatment of hypertension and Cushing's Syndrome | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| EP-2007770-B1 | IMIDAZO COMPOUNDS | NOVARTIS AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| EP-2007771-B1 | IMIDAZO COMPOUNDS | NOVARTIS AG (CH) | 2010-04-07 | — | — | EP | disclosed |
| US-20090192149-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192149-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192149-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192144-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192144-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| WO-2007116101-A1 | IMIDAZO COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007116099-A1 | IMIDAZO COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192149-A1 | Imidazo Compounds | CYP19A1, CYP11B2, GPER1 | CYP19A1 1/4885CYP11B1 4/4885CYP11B2 2/4885 |
| US-20090192144-A1 | Imidazo Compounds | REN, CYP11B2, CYP11B1 | CYP19A1 70/4885CYP11B1 3/4885CYP11B2 2/4885 |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | REN, CYP11B2, CYP11B1 | CYP19A1 84/4885CYP11B1 3/4885CYP11B2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.